ARISTO — Aristo Bio-Tech and Lifescience Income Statement

0.000.00%

Last trade - 00:00

Basic MaterialsSpeculativeMicro CapContrarian

Annual income statement for Aristo Bio-Tech and Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,660	2,179	2,451	3,181	3,637
Cost of Revenue
Gross Profit	189	221	194	226	329
Selling / General / Administrative Expenses
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	1,616	2,107	2,382	3,114	3,506
Operating Profit	43.6	71.7	69.2	66.7	131
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	20.4	47.4	54.1	54.7	97
Provision for Income Taxes
Net Income After Taxes	14.5	35.6	39	40.6	71.8
Net Income Before Extraordinary Items
Net Income	14.5	35.6	39	40.6	71.8
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	14.5	35.6	39	40.6	71.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.11	5.23	5.72	5.89	10.5
Dividends per Share